argenx SE (A1RG34) - Net Assets
Based on the latest financial reports, argenx SE (A1RG34) has net assets worth R$7.32 Billion BRL as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (R$8.68 Billion) and total liabilities (R$1.36 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | R$7.32 Billion |
| % of Total Assets | 84.34% |
| Annual Growth Rate | 30.38% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 12.53 |
argenx SE - Net Assets Trend (2021–2025)
This chart illustrates how argenx SE's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for argenx SE (2021–2025)
The table below shows the annual net assets of argenx SE from 2021 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | R$7.32 Billion | +33.19% |
| 2024-12-31 | R$5.50 Billion | +34.19% |
| 2023-12-31 | R$4.10 Billion | +45.63% |
| 2022-12-31 | R$2.81 Billion | +11.03% |
| 2021-12-31 | R$2.53 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to argenx SE's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 112042800000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | R$7.60 Billion | 103.82% |
| Total Equity | R$7.32 Billion | 100.00% |
argenx SE Competitors by Market Cap
The table below lists competitors of argenx SE ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Discover Financial Services
NYSE:DFS
|
$50.34 Billion |
|
Petroleo Brasileiro S.A.
MC:XPBRA
|
$50.40 Billion |
|
Itau Unibanco Banco Holding SA
NYSE:ITUB
|
$50.46 Billion |
|
MetLife Inc
NYSE:MET
|
$50.52 Billion |
|
Ferrovial SE
NASDAQ:FER
|
$50.27 Billion |
|
NAURA Technology Group Co Ltd
SHE:002371
|
$50.23 Billion |
|
BOC Hong Kong (Holdings) Limited
F:BOF
|
$50.17 Billion |
|
Cardinal Health Inc
NYSE:CAH
|
$50.15 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in argenx SE's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,498,283,000 to 7,323,092,000, a change of 1,824,809,000 (33.2%).
- Net income of 1,292,035,000 contributed positively to equity growth.
- Other factors increased equity by 532,774,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | R$1.29 Billion | +17.64% |
| Other Changes | R$532.77 Million | +7.28% |
| Total Change | R$- | 33.19% |
Book Value vs Market Value Analysis
This analysis compares argenx SE's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.39x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.36x to 1.39x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | R$49.05 | R$164.96 | x |
| 2022-12-31 | R$50.79 | R$164.96 | x |
| 2023-12-31 | R$69.22 | R$164.96 | x |
| 2024-12-31 | R$90.49 | R$164.96 | x |
| 2025-12-31 | R$118.34 | R$164.96 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently argenx SE utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 17.64%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 31.11%
- • Asset Turnover: 0.48x
- • Equity Multiplier: 1.19x
- Recent ROE (17.64%) is above the historical average (-3.15%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -16.11% | -82.10% | 0.17x | 1.12x | R$-661.69 Million |
| 2022 | -25.22% | -172.76% | 0.13x | 1.11x | R$-990.96 Million |
| 2023 | -7.20% | -24.06% | 0.27x | 1.11x | R$-704.80 Million |
| 2024 | 15.15% | 38.03% | 0.35x | 1.13x | R$283.21 Million |
| 2025 | 17.64% | 31.11% | 0.48x | 1.19x | R$559.73 Million |
Industry Comparison
This section compares argenx SE's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $191,479,000
- Average return on equity (ROE) among peers: -36.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| argenx SE (A1RG34) | R$7.32 Billion | -16.11% | 0.19x | $50.32 Billion |
| Biomm S.A (BIOM3) | $191.48 Million | -36.96% | 1.27x | $198.70 Million |
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develo… Read more